Spectral to present at Wedbush Life Sciences Conference

CNW Group

TORONTO , Aug. 1, 2013 /CNW/ - Spectral Diagnostics Inc., (SDI.TO) (DIAGF), a Phase III company developing the first theranostic treatment for patients with severe sepsis and septic shock, today announced that the Company's President and CEO, Dr. Paul Walker , will be presenting a corporate overview at the Wedbush Life Sciences Management Access Conference in New York on Wednesday, August 14, 2013 , at 1:20 p.m. ET .

A live webcast will be available on Spectral's website, www.spectraldx.com. The webcast will also be archived and available for replay for 90 days.

About Spectral Diagnostics
Spectral is a Phase III company seeking U.S. FDA approval for its lead theranostics product for the treatment of severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. Spectral's EUPHRATES trial is the world's first theranostics trial in the area of sepsis.

Toraymyxin has been approved for therapeutic use in Japan and Europe , and has been used safely and effectively on more than 100,000 patients to date. In March 2009 , Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin, and in November 2010 , signed an exclusive distribution agreement for this product in Canada . More than 350,000 patients are diagnosed with severe sepsis and septic shock in North America each year, representing a greater than $1 billion market opportunity for Spectral. Spectral is listed on the Toronto Stock Exchange under the symbol SDI, and on the OTCQX under the symbol DIAGF. For more information please visit www.spectraldx.com

SOURCE: Spectral Diagnostics Inc.

Contact:

Anthony Businskas
Executive Vice President and CFO
416-626-3233 ext. 2200

Adam Peeler
Investor Relations
TMX Equicom
416-815-0700 ext. 225
apeeler@tmxequicom.com

Rates

View Comments (0)